Every Form 4 that Design Therapeutics, Inc. (DSGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DSGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DSGN filings page.
Design Therapeutics director and 10% owner George Simeon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. They vest in equal monthly installments over 12 months after June 9, 2026, or will be fully vested by the company’s next annual stockholder meeting.
Design Therapeutics, Inc. director John P. Schmid received a grant of stock options covering 30,000 shares of common stock. These options have an exercise price of $10.55 per share and expire on June 8, 2036.
The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. After this grant, Schmid holds options on 30,000 shares directly.
Design Therapeutics, Inc. director Rodney W. Lappe received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036.
According to the disclosure, these options were awarded as compensation and will vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the company’s next annual stockholder meeting. Following this grant, Lappe holds derivative securities representing 30,000 underlying shares directly.
Design Therapeutics, Inc. reported that director Justin D. Gover received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. The award vests in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. Following this grant, Gover holds 30,000 stock options directly.
Design Therapeutics, Inc. director David Shapiro received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.55 per share and expires on June 8, 2036. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. This is a compensation-related award, not an open-market purchase or sale.
Design Therapeutics, Inc. director Heather A. Berger received a grant of stock options covering 30,000 shares of Common Stock at an exercise price of $10.55 per share. These options now represent 30,000 derivative securities held directly after the transaction.
The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders, aligning vesting with ongoing board service.
Design Therapeutics director David Shapiro received new stock option awards, increasing his potential equity stake without any open-market trading. On March 31, 2026, he was granted options for 60,000 shares of common stock at an exercise price of $10.64 per share, expiring March 30, 2036. These options vest in equal monthly installments over 36 months following March 31, 2026. He also received a separate option for 7,500 shares at the same $10.64 exercise price, expiring March 30, 2036, vesting in equal monthly installments over 12 months following March 31, 2026. Both grants are reported as direct ownership and represent compensation awards rather than share purchases or sales.
Design Therapeutics disclosed that its President, CEO and Chairperson, who also serves as a director, holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share, originally granted on September 1, 2023.
The option was subject to both time-based vesting and a specific performance condition. On December 9, 2025, the board determined that the performance condition had been met, causing 295,312 of these option shares to vest. The remaining unvested portion is scheduled to vest in equal monthly installments through August 25, 2027, as long as the executive continues to provide service to the company.